Edwards Lifesciences (EW) Total Current Liabilities (2009 - 2026)

Edwards Lifesciences' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 1.02% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 1.02% YoY), while the FY2025 annual figure was $1.8 billion, up 20.5% from the prior year.
• Total Current Liabilities was $1.4 billion for Q1 2026 at Edwards Lifesciences, down from $1.8 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.9 billion in Q3 2024 to a low of $917.9 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 56.92% in 2024, then slipped 18.32% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $1.0 billion in 2022, then advanced by 16.92% to $1.2 billion in 2023, then gained by 25.92% to $1.5 billion in 2024, then rose by 20.5% to $1.8 billion in 2025, then declined by 22.31% to $1.4 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.4 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.